Respiratory Institute Outcomes
Pulmonary Vascular Program
Pulmonary Vascular Program
The COVID-19 pandemic created challenges never seen before by the Pulmonary Vascular Program. The program resorted to virtual platforms to remain connected to our patients, while ensuring that those who needed in person care were appropriately identified and supported. The Pulmonary Vascular Program at Cleveland Clinic consists of a team of 7 pulmonologists, 2 cardiologists, 2 advanced practice nurses, a nurse, 2 program coordinators, and 2 research coordinators. Additionally, as part of Cleveland Clinic, the program draws on expertise in cardiology, cardiothoracic surgery, lung transplantation, hepatology, liver transplantation, sleep medicine, rheumatology, hematology, and interventional radiology to provide a comprehensive and multidisciplinary approach to patient care. Active clinical and research programs are offered for all types of pulmonary hypertension, including idiopathic pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, hereditary hemorrhagic telangiectasia, portopulmonary hypertension, congenital heart disease, and pulmonary hypertension associated with the scleroderma spectrum of diseases and other connective tissue diseases. The program offers advanced hemodynamic evaluation including invasive cardiopulmonary exercise testing (ie, simultaneous right heart catheterization and cardiopulmonary exercise testing) and maintains an Institutional Review Board-approved comprehensive registry.
The Pulmonary Vascular Program is involved in a wide range of research activities, from NIH-funded basic research and translational research to clinical trials of the latest therapies. Many patients referred to the program benefit from enrollment in 1 or more of these ongoing clinical trials and research studies.
Patients Entered in the Pulmonary Hypertension Registry (N = 2,829)
|Category||Number of Patients|
|Pulmonary Arterial Hypertension|
|Left Heart Disease|
|Lung Disease and/or Hypoxia|
|Chronic Thromboembolic Pulmonary Hypertension||432|
|Unclear or Multifactorial||178|
Pulmonary Artery Catheterization Volume
2015 – 2020
CPET = cardiopulmonary exercise test
Actual and Predicted Survival of Patients with Category 1 Pulmonary Arterial Hypertension (N = 1,071)
Pulmonary Hypertension Patients Who Tested Positive for COVID-19 at Cleveland Clinic (N = 41)
March 2020 – February 2021
|Outcome||Death (N = 5)||Survival (N = 36)|
|Age mean (SD)||67 (6)||58 (14)|
|ICU Stay||3 (60%)||4 (11%)|
|Hospitalization||3 (60%)||13 (36%)|
The COVID-19 pandemic had an impact on the operation of the Pulmonary Vascular Program. SARS-CoV-2 infection might have direct implications for pulmonary hypertension patients .³ Among 636 patients with all forms of pulmonary hypertension actively followed by the program, 41 cases were observed with COVID-19 (6.4% of the cohort), and 5 of 41 patients died (mortality 12%).